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ABSTRAK
Rawatan konvensional laser argon menyebabkan ketebalan sementara pada lapisan 
saraf retina (RNFL). Tetapi kesan dari ‘pattern scanning laser’ (PASCAL) tidak banyak 
diketahui. Kajian ini dilakukan untuk membandingkan kesan selepas konvensional 
laser argon dibandingkan dengan PASCAL pada pesakit yag mengalami masalah 
diabetik retinopati. Sebanyak 32 subjek telah terpilih dalam kajian ini. Seramai 16 
pesakit dalam kumpulan argon dan 16 pesakit dalam kumpulan PASCAL. Pesakit 
yang terlibat diambil dari klinik mata, Pusat Perubatan Universiti Kebangsaan 
Malaysia (PPUKM). Pemeriksaan mata yang lengkap dan gambar fundus dilakukan 
pada awal kajian, selepas 2 bulan dan 4 bulan dilaser. RNFL diukur menggunakan 
domain masa tomografi koheren optikal (OCT). Kedua kumpulan mempunyai ciri 
klinikal yang sama sebelum rawatan (p= 0.323). RNFL selepas laser argon tidak 
berubah secara signifikan dalam semua kuadran pada bulan ke 2 dan 4 selepas 
rawatan. Namun, untuk kumpulan PASCAL, perubahan sigifikan telah ditemui pada 
bulan ke 4 rawatan pada ‘average RNFL’ dan RNFL ‘inferior’ (p<0.05). Bahagian 
lain menunjukkan kenaikan ketebalan RNFL tetapi tidak signifikan secara statistik. 
Sebagai kesimpulan, kenaikan RNFL berlaku pada kedua-dua kumpulan. Pesakit 
PASCAL mengalami lebih ketebalan. Dengan itu, adalah perlu mengambil kira 
kejadian laser yang baru berlaku jika mahu menganalisa ketebalan RNFL.
Kata kunci: fotokoagulasi, optikal koheren tomografi, retinopati diabetes, sel retinal 
gaanglion, tomografi
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 The principle by which the laser 
exerts its therapeutic effects relies on 
the destruction of the outer retina. 
This reduces the oxygen demand 
while maintaining a constant oxygen 
input. Laser burns may also serve as 
physiological windows through which 
oxygen diffuses from the choroid, 
increasing vitreous oxygenation and 
induced vasoconstriction (Velez-
Montota et al. 2010). However, despite 
the efficacy for preventing severe visual 
loss, laser PRP is often associated with 
substantial ocular side effects, such as 
ABSTRACT
Conventional argon laser causes transient thickening of retinal nerve fibre layer 
(RNFL). The effect of pattern scanning laser (PASCAL) has not been well described. 
We compared the immediate changes in peripapillary RNFL thickness post-panretinal 
photocoagulation between conventional argon lasers and PASCAL in patients with 
diabetic retinopathy changes. A total of 32 subjects were recruited. There were 16 
patients in the argon group and 16 patients in PASCAL group. Diabetic patients were 
recruited from Ophthalmology Clinic, Universiti Kebangsaan Malaysia Medical 
Centre (UKMMC). Complete eye examinations and fundus photographs were 
performed at baseline prior to laser treatment, and post-laser treatment at two and 
four months. RNFL thickness was measured using time domain optical coherence 
tomography. Both groups were comparable with respect to clinical characteristics 
and demographics. There was no significant difference in average RNFL thickness 
between the two groups prior to treatment (p= 0.323). RNFL post-laser treatment for 
patients receiving conventional argon laser remained unchanged with no significant 
differences in all quadrants at any time-point (two and four months). However, for 
the PASCAL group, significant thickening occurred at four months for average RNFL 
and the inferior quadrant (p <0.05). The other quadrants similarly demonstrated 
increasing thickness at four months but this did not reach statistical significance. 
Transient RNFL thickening occurs in both conventional and PASCAL laser patients. 
The PASCAL laser induces a greater increase in RNFL thickness than the argon laser 
group. Important events, such as laser eye treatments and even type of laser used, 
are worthy of consideration when evaluating RNFL. 
Keywords: diabetic retinopathy, optical coherence, photocoagulation, retinal ganglion 
cells, tomography
INTRODUCTION 
Microvascular complications of diabetes 
dominated as the leading cause of 
preventable blindness in working aged 
people in many developed countries 
(Cheung et al. 2010). Over the past 30 
years, pan retinal photocoagulation 
(PRP) has remained as the gold standard 
for treating ischemic and neovascular 
diseases of the retina.  PRP reduces 
the risk of severe visual loss by 50% 
in patients with high risk proliferative 
diabetic retinopathy (DRSRG 1978).
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difficulty with light–dark adaptation, a 
slight decrease in vision, and peripheral 
visual loss (Pender et al. 1981; Henson 
& North 1979).
 The energy of a conventional argon 
laser is transformed to heat at the level 
of the retinal pigment epithelium (RPE) 
and the outer retinal layer. However, 
longer laser wavelengths will penetrate 
deeper than the RPE and cause more 
destructive changes to the retina, RPE, 
and choriocapillaris (Maeshima et 
al. 2004; Nagpal et al. 2010). Pattern 
scanning laser (PASCAL) is a novel device 
that has radically changed traditional 
laser parameters. Normal conventional 
laser requires an average duration of 
average of 100 ms compared to only 
20 ms for PASCAL. Velez-Montoya et 
al. (2010) demonstrated short duration 
of PASCAL laser allows lower total 
energy used to produce a desired burn. 
This consequently limits the spreading 
of choroidal heating and elicits a more 
uniform energy distribution with less 
inner retinal injury (Muqit et al. 2010a). 
Another major advantage of PASCAL 
is the ability to distribute the laser 
treatment over a wider area of the retina 
in a single session with less collateral 
damage (Nagpal et al. 2010). At the 
same time, retinopathy regression was 
similar to the conventional argon green 
laser (Nagpal et al. 2010).
 Argon laser has long since been 
known to cause a significant reduction 
in RNFL thickness over time (Kim & Cho 
2009). Transient thickening post-PRP 
with the conventional argon laser has 
also been described by many authors 
(Kim & Cho 2009). However, the effect 
of PASCAL on peripapillary RNFL 
thickness has not been well described. 
Therefore, this study was designed to 
compare the immediate changes in 
peripapillary RNFL thickness post-PRP 
between conventional argon lasers and 
PASCAL. 
MATERIALS AND METHODS
This was a hospital based, randomized 
clinical trial study. It was conducted 
at UKMMC, Kuala Lumpur, Malaysia. 
Ethical approval was obtained from 
the Research and Ethics Committee 
of Faculty of Medicine, Universiti 
Kebangsaan Malaysia. The study 
was conducted from March 2011 to 
December 2012. Written consent was 
obtained from all the participants. 
PARTICIPANTS
Recruited patients included those 
with proliferative diabetic retinopathy 
(PDR) or very severe non-proliferative 
diabetic retinopathy (NPDR) requiring 
PRP laser treatment. An experienced 
ophthalmologist clinically graded the 
stages of diabetic retinopathy and 
diagnosis was made based on the early 
treatment diabetic retinopathy study 
(ETDRS) classification. Patients were 
randomized into two groups based on 
the treatment received: conventional 
argon laser or PASCAL. 
 Inclusion criteria were: i) type 2 
diabetes mellitus with very severe 
NPDR or PDR requiring laser treatment; 
ii) clear media without clinically 
significant amount of cataract; iii) age 
of diabetes mellitus diagnosis >35 years; 
iv) and best corrected vision of 6/18 or 
better to ensure good signal strength 
on optical coherence tomography 
(OCT). Exclusion criteria were: i) type 
202
Med & Health 2016;11(2): 199-208 Maimunah M. et al.
1 diabetes mellitus; significant media 
opacity; ii) co-existing glaucoma; iii) 
previous laser treatment or eye surgery; 
iv) degenerative myopia or uveitis; v) or 
any history of other vascular diseases, 
such as retinal artery or vein occlusion. 
DATA COLLECTION
Complete eye examinations, fundus 
photographs,and OCT (Carl Zeiss 
Meditec Inc., Dublin, CA) measurement 
of the peripapillary RNFL were 
performed prior to laser and post-
treatment at two and four months. A 
3.4 mm peripapillary scan mode was 
used to measure peripapillary RNFL 
thickness. Patients with good signal 
strength on OCT (>5) were included. 
 A single, medically trained person 
performed the PRP. A total of 900 to 
1,500 laser spots were generated at each 
sitting. Time interval of one to two weeks 
was maintained between two sittings. A 
laser spot size of 200 or 300 µm was 
used for both modalities. Pulse duration 
of 20 ms was used for PASCAL and 100 
ms for the argon laser. The power was 
adjusted to achieve gray burns. Spots 
were placed one spot distance apart. 
Topical anesthesia was used in all eyes. 
Among completing the treatment, total 
number of laser spots in each eye ranged 
from 2,000 to 3,000 shots. Treatment 
was considered complete once there 
was clinical evidence of regression of 
neovessels, and intraretinal hemorrhage, 
improvement in venous dilatation, and 
no new pre-retinal bleed. Pallor of the 
disc was unlikely to be observed at four 
months post-laser. Therefore, it was 
not used as an indication of disease 
regression. 
ETHICAL APPROVAL
The research was approved by the 
Ethics committee of UKMMC (FF-2010-
347). The privacy and confidentiality 
of each individual was maintained and 
the respondents were given the rights to 
withdraw from participation.
DATA ANALYSIS
The statistical analysis in this study was 
presented descriptively. Univariate, 
bivariate, and multivariate analyses were 
performed using the Statistical Package 
for Social Sciences (SPSS) version 20.0 
(IBM Corp, Armonk, NY, USA). The 
differences in RNFL thickness were 
analyzed using paired t-tests (normal 
data), whereas the Chi-square test was 
used for categorical data and general 
linear models (repeated measurement 
analysis of variance [ANOVA]) were 
used for multivariate analysis. A 
p-value less than 0.05 was accepted as 
statistically significant.
RESULTS
DEMOGRAPHIC INFORMATION
A total of 32 subjects were recruited for 
the study; 16 patients in the argon group 
and 16 patients in the PASCAL group, 
and 27 patients had PDR and five had 
very severe non-PDR. The mean age for 
the argon group was 56.44 ± 7.87 yrs 
and Pascal group was 54.00 ± 7.94 yrs 
(p=0.390). The overall age range of both 
groups was 41 to 78 yrs. The duration 
of diabetes was comparable between 
the two groups with a mean duration 
for patients receiving argon laser of 
7.31 ± 4.81 yrs and for the PASCAL 
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group 6.75 ± 3.75 yrs (p = 0.71). Table 
1 summarised the demographic data 
and clinical characteristics of the study 
population. 
PERIPAPILLARY RETINAL NERVE 
FIBER LAYER THICKNESS CHANGES 
IN THE CONVENTIONAL ARGON 
GROUP 
Average RNFL before laser treatment 
was 108.64 ± 17.70 μm, and a slight 
increase was noted at two months post-
treatment (112.64 ± 17.05 μm; p=0.127). 
Baseline RNFL before treatment was 
used as comparison. Subsequently, 
at four months, average RNFL was 
106.55 ± 15.77µμm (p=0.457). 
Analysis of the individual quadrants 
(temporal,nasal,superior and inferior) 
showed similar transient thickening 
of the RNFL at two months, except 
for the nasal quadrant. Superior RNFL 
measurements prior to laser, at two 
and four months were 127.75 ± 22.12 
μm, 132.38 ± 21.99 μm (p=0.200), 
and 126.69 ± 20.36 μm, respectively 
(p=0.795). Nasal quadrant thickness was 
the only quadrant that showed a slight 
reduction in thickness from baseline 
after laser treatment: 86.31 ± 21.33 μm, 
79.58 ±  24.41 μm (p= 0.404), and 80.63 
± 19.49 μm, respectively (p=0.366). 
 Although the transient thickening 
at two months was not statistically 
significant, there was a consistent 
trend of thickening observed in all 
quadrants except for the nasal region 
(Table 2, Figure 1). These changes were 
temporary and RNFL in all quadrants 
recovered to baseline thickness at four 
months. 
PERIPAPILLARY RETINAL NERVE 
FIBER LAYER THICKNESS 
CHANGES IN THE PASCAL 
GROUP 
Conversely in the PASCAL group, 
RNFL showed continuous significant 
thickening at two and four months post 
laser treatment. Significant changes 
were found for the average RNFL at two 
and four months, inferior RNFL at four 
Table 1: Demographic and clinical characteristics at the baseline. 
Argon Pascal P-value
No. of eyes/patients 16 16
Sex
Male 8(53.3) 7(46.7)
Female 8(47.1) 9(52.9)
Age, years 56.44 ± 7.87 (range) 54.00 ± 7.94 (range) 0.390
Duration, years 7.31 ± 4.81 6.75 ± 3.75 0.71
Type of DR
PDR 15(55.6) 12(44.4)
Very severe NPDR 1(20.0) 4(80.0)
Baseline RNFL pre-laser 108.64 ± 17.70 99.26 ± 13.96 0.107
Data are means ±SD (range), absolute values (%). PDR, proliferative diabetic retinopathy; NPDR, non-
proliferative diabetic retinopathy; RNFL, retinal nerve fiber layer; SD, standard deviation. 
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months and nasal quadrant at two and 
four months. Average RNFL thickness 
before laser treatment was 99.26 ± 
13.96 μm, 105.52 ± 17.39 μm at two 
months (p=0.003), and 107.20 ± 12.14 
μm (p = 0.001) at four months (Table 3, 
Figure 2).
 Overall, in the PASCAL group, 
increasing trend of RNFL thickness 
occurred in all quadrants with time. 
Compared to the argon group, RNFL 
thickness  failed to return to its baseline 
level at four months.
DISCUSSION 
Histologically, Blumenkrantz et al. 
(2006) reported application of 100 
ms threshold level of 514 nm argon 
green laser in rabbit eyes produced a 
complete loss of the photoreceptors 
as well as hyperplasia of the pigment 
epithelium). High powered lasers 
cause transmission of heat to adjacent 
tissue causing destructive effects and 
inflammatory response immediately 
after laser treatment. This transmitted 
Table 2: Peripapillary retinal nerve fiber layer thickness changes before and after laser 
in the argon group.
Measurements 
in different  
quadrants
Pre -Laser 
(μm ±SD)
Post-Laser 2 months 
(μm ± SD)
Post-Laser 4 months 
(μm ± SD) P-value* P-value”
Average 108.64 ± 17.70 112.64 ± 17.05 106.55 ± 15.77 0.127 0.457
Superior 127.75 ± 22.12 132.37 ± 21.99 126.69 ± 20.36 0.200 0.795
Inferior 138.25 ± 28.21 140.69 ± 25.65 134.12 ± 25.29 0.659 0.385
Nasal 86.31 ± 21.33 79.58 ± 24.41 80.63 ± 19.49 0.404 0.366
Temporal 79.81 ± 14.37 90.81 ± 22.28 85.19 ± 13.44 0.053 0.102
 
Paired-sample t-test.
*P-value <0.05 corresponding to pre-laser and 2 monthspost-laser.
“P-value <0.05 corresponding to pre-laser and 4 monthspost-laser.
Figure 1: Peripapillary retinal nerve fiber layer thickness changes before and after laser in the argon 
group.
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effect predisposes patients not only 
to macular edema due to transient 
choroidal thickening, but, in the long 
run, increases the risk of developing 
epiretinal membranes (Kim & Cho 
2009). Moreover, the end point laser 
marks tend to exaggerate with time, 
which correlates well with reported 
histological data (Maeshima et al. 
2004). Such effects are well tolerated 
in older age groups, but with the 
increasing number of young diabetics 
(Geiss et al. 2014), these side effects 
may significantly affect their quality of 
life. 
 The aim of new laser technologies 
is to achieve retinal photocoagulation 
that causes healing responses by 
selectively targeting the RPE with 
minimal photoreceptor loss and scar 
expansion. PASCAL uses a special 
scanning pattern to permit rapid 
photocoagulation, and thus reduces 
burn session time, improving patient 
Table 3: Peripapillary retinal nerve fiber layer thickness changes before and after laser 
in the PASCAL group.
Measurements 
in different  
quadrants
Pre-Laser 
(μm ± SD)
Post-Laser  2 months 
(μm ± SD)
Post-Laser 4 months 
(μm ± SD) P-value* P-value”
Average 99.26 ± 13.96 105.52 ± 17.39 107.20 ± 12.14 0.003 0.001
Superior 118.81 ± 18.26 123.69 ± 26.48 122.19 ± 16.75 0.311 0.213
Inferior 130.88 ± 23.75 135.25 ± 23.95 140.06 ± 21.28 0.291 0.021
Nasal 66.44 ± 17.60 79.06 ± 22.10 80.69 ± 16.38 0.280 0.00
Temporal 82.75 ± 25.81 82.75 ± 17.95 85.38 ± 24.76 1.00 0.712 
Paired-sample t-test.
*P-value < 0.05 corresponding to pre-laser and 2 monthspost-laser.
“P-value < 0.05 corresponding to pre-laser and 4 monthspost-laser.
Figure 2: Peripapillary retinal nerve fiber layer thickness changes before and after laser in the 
PASCAL group.
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comfort as well as ensuring excellent 
physician performance and efficiency 
(Blumenkranz et al. 2006; Muqit et al. 
2012). PASCAL technology is a semi-
automated pattern generation method 
using short laser pulse durations of 
typically 20 ms (five times shorter than 
conventional systems). Moreover, argon 
lasers and PASCAL have been proven 
to be equally effective for treating 
proliferative diabetic retinopathy 
(Naqpal et al. 2010). OCT observations 
by Inagaki et al. (2012) showed that the 
PASCAL laser reduces the vertical and 
horizontal spread of laser energy, thus 
producing shorter defect in the inner/
outer segment line compared to the 
conventional laser group.
 Apart from limited injury to the 
entire retina, PASCAL laser scars were 
not found to enlarge with time (Muqit 
et al. 2010b). Histopathology evaluation 
by Paulus et al. (2013) reported 
preservation of the inner nuclear layer 
of RNFL post PASCAL laser. Previous 
OCT study, describe transient RNFL 
thickening occurs immediately after 
argon laser treatment and may last 
for up to 6 months (Lee et al. 2013). 
As opposed to our study, transient 
thickening in our study did not last 
beyond four months. The cause of this 
transient thickening remained uncertain 
although many authors postulated the 
presence of upragulated inflammatory 
mediators occur post laser treatment. 
Nonaka et al. (2002) reported increase 
number of leukocytes and vascular 
permeability, which resulted in retinal 
edema post-lase).
 To the best of our knowledge, there 
is no previous study reporting changes 
in peripapillary RNFL thickness after 
PASCAL laser in diabetic patients, let 
alone comparing conventional argon 
to PASCAL laser. It is interesting to note 
that, in the present study, the PASCAL 
laser produced more thickening of 
the peripapillary RNFL compared to 
the argon group immediately after 
multi-session PRP. Also, the increased 
thickening continued to progress even 
at four months post treatment. The 
common argon laser setting for retinal 
ablation was 100–200 ms duration and 
the power used ranged from 150–350 
mW. The PASCAL laser, on the other 
hand, uses higher power to deliver the 
same amount of energy with extremely 
shorter pulse duration of 10 ms (Lee et al. 
2013). Therefore, in general the amount 
of energy received by the lasered area 
is lower compared to the conventional 
argon treatment (Velez-Montoya et 
al. 2010). The possible explanation at 
this point is the probability of higher 
power used during PASCAL laser 
induces greater inflammatory responses 
compared to the argon laser. Paulus et 
al. (2011) in another study, described the 
histological changes of retina in rabbits 
post pascal laser. Spot size used was less 
than 60um with lacking of description 
on the power used. The authors 
observed accumulation of oedema 
between the outer segment and RPE 
layer. Resolution was seen as early as 
one month with persistent preservation 
of the inner retinal layer (Paulus et al. 
2011). Similar observation might occur 
in vivo. However, direct comparison 
with our findings might not be feasible. 
Despite uncertain explanation for the 
persistent peripapillary retinal swelling in 
our study, it is important to note that the 
retinal cells react differently with PACAL 
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laser.  Evaluation of peripapillary RNFL 
in such cases immediate post laser will 
not represent the actual RNFL thickness 
and has to be evaluated with caution. 
 Although the limitations of this 
study were due to the short duration of 
follow-up, our findings are significant 
enough to indicate a difference in 
tissue response between these two 
treatment modalities. Longer follow-
up in larger study scale might help to 
determine the onset of RFNL thickening 
resolution that is known to occur with 
time. Another limitation involved the 
use of time domain OCT which is the 
earlier version of biomicroscope. Time 
domain OCT was the only machine 
available during the study period. 
Therefore, future study design the 
latest spectral domain OCT will be 
able provide additional biomicroscope 
changes and offer better explanation 
for such changes. 
 In conclusion, transient thickening 
of the RNFL occurs post-PRP in both 
conventional and PASCAL laser patients. 
However, the PASCAL laser seems to 
produce more cellular reaction, hence 
increases the RFNL thickness to a greater 
extent than the argon laser group. This 
is important as RFNL measurements 
have been incorporated as one of the 
gold standards of glaucoma evaluation. 
Important events, such as laser 
treatment to the eye and type of laser 
used worth of consideration during 
OCT evaluation of RNFL thickness in 
such cases.
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